Jun 02, 2022 / 08:30PM GMT
Operator
Good afternoon, and welcome to the Aptose Biosciences KOL data call. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the Aptose website following the conclusion of the event.
I'd now like to turn the call over to Dr. William Rice, President and Chief Executive Officer of Aptose Biosciences. Please go ahead, William.
William G. Rice - Aptose Biosciences Inc. - Chairman, President, CEO & CAO
Thank you, Tera. Good day all, and thank you for joining us. I am Dr. William Rice, Chairman, President and CEO of Aptose Biosciences. Aptose is a clinical stage biotech company, developing oral kinase inhibitors for the treatment of patients with hematologic malignancies. And today, we'll hold an AML-focused KOL event and a high-level update on our clinical programs. And as a reminder, we will make certain forward-looking statements today.
At Aptose, we're developing 2 distinct clinical-stage oral kinase inhibitors. Our most advanced molecule, HM43239 or just 239 as we call it, is a clinically
Aptose Biosciences Inc To Hold KOL Event And Corporate Update Call Transcript
Jun 03, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers